ALAMEDA, Calif., Jan. 21, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the fourth quarter and full year 2024 after market close on Tuesday, February 18, 2025 at 4:30 PM Eastern Time. A press release with fourth quarter and full year 2024 financial results will be issued after market close that day.Webcast & Conference Call InformationThe conference call can be accessed live over the phone by dialing (888) 596-4144 (confe ...

Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. But finding a growth stock that can live up to its true potential can be a tough task.By their very nature, these stocks carry above-average risk and volatility. Moreover, if a company's growth story is over or nearing its end, betting on it could lead to significant loss.However, it's pretty easy to find cutting-edge growth stocks with the ...

Penumbra (PEN) shares rallied 6.3% in the last trading session to close at $252.23. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 1.5% loss over the past four weeks.Penumbra scored a strong price increase driven by optimism surrounding Stryker's entry into the high-growth mechanical thrombectomy (“MT”) sector with the acquisition of Inari Medical, Inc. A notable competitor like Stryker implies greater focus ...

Robust improvement of Penumbra, Inc.’s (PEN) Thrombectomy business is poised to help the company grow in the upcoming quarters. PEN expects impressive growth as it plans to expand globally in the coming years. A robust solvency position also bodes well for the stock. Meanwhile, unfavorable foreign exchange remains a concern for Penumbra.  In the past six months, shares of this Zacks Rank #2 (Buy) company have rallied 32.4% compared with the industry’s 0.3% growth and the S&P 500 composite’s 6.8% gain.The gl ...

ALAMEDA, Calif., Dec. 30, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025. Event:     43rd Annual J.P. Morgan Healthcare ConferenceDate:       Monday, January 13, 2025Time:      6:00pm ET/3:00pm PT A webcast of the presentation can be accessed on the "Events and Presentations" section under the "Investors" tab of the company's website at www.penumbrainc.com.  The ...

Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. But finding a great growth stock is not easy at all.That's because, these stocks usually carry above-average risk and volatility. In fact, betting on a stock for which the growth story is actually over or nearing its end could lead to significant loss.However, it's pretty easy to find cutting-edge growth stocks with the help of the Zacks Gro ...

Throughout 2024, MedTech stocks held a significant position in the portfolio of several investors. Despite several macroeconomic softnesses, the dynamic nature of the sector, marked by innovation and resilience, attracted investors throughout the year. The industry experienced significant growth and innovation, driven by technological advancements and increasing demand for personalized healthcare solutions. As the healthcare landscape continues to evolve, the MedTech sector, encompassing medical devices, di ...

Shares of Penumbra Inc PEN recovered slightly in early trading on Tuesday, after a week of correction.The Alameda, California-based company is likely to gain market share in the mechanical thrombectomy (MT) segment, according to Oppenheimer.MT is a minimally invasive procedure that removes a blood clot from an artery.Analyst Steven Lichtman initiated coverage of Penumbra with an Outperform rating and a price target of $275.The Penumbra Thesis: The company could generate mid-teens sales growth and over 30% e ...

Penumbra, Inc.’s (PEN) robust portfolio expansion efforts are poised to help it grow in the upcoming quarters. The company expects impressive growth as it expands globally throughout the rest of 2024 and beyond. A robust solvency position also bodes well for the stock. Meanwhile, macroeconomic volatilities and fiercely competitive space remain a concern for Penumbra.  In the past year, shares of this Zacks Rank #2 (Buy) company have rallied 7.1% compared with the industry’s 14.5% growth and the S&P 500 comp ...

Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. However, it isn't easy to find a great growth stock.That's because, these stocks usually carry above-average risk and volatility. In fact, betting on a stock for which the growth story is actually over or nearing its end could lead to significant loss.However, the Zacks Growth Style Score (part of the Zacks Style Scores system), which looks ...